Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Novo Nordisk Archives
Print | Email | Share | Comments (16)

Insulin Pen Instead of Syringe Saves Hospital Bills For Type 2s


Mar 21, 2009

Since Novo Nordisk recently released an improved FlexPen in the United States, we thought we’d remind you of one of their values.

Type 2s who start their insulin with pens end up requiring much less medical care.

In a study funded by Novo Nordisk, researchers at Ohio State University have found that type 2s who move from oral meds to insulin would be wise to start with an insulin pen rather than a syringe.

It's not because the pens cost less than syringes and vials; in fact, they cost more. Rather, it's because type 2s who start their insulin with pens end up requiring much less medical care.

The researchers compared 1,162 type 2 Medicaid patients who began insulin therapy with syringes to 168 who began insulin by using Novo Nordisk insulin pens. They found that only about half the people in either group took their insulin properly, a fact that they attributed to the poor overall care that low-income people receive from Medicaid.

After summing up the costs of each group's emergency room visits, hospitalizations, and outpatient visits for diabetes-related conditions, the average cost for pen users was $14,857 a year. For syringe users, however, it was a whopping $31,764.

In another study, the same researchers compared more than 1,100 patients who were already on insulin when the study began. Half switched to a pen, and half stayed on injections. In that study, annual healthcare costs of pen users were more than for syringe users: $11,476 versus $10,755.

The researchers explained this contradictory finding by noting that pens are more expensive initially. They also hypothesized that pen users probably took their insulin as often as they were supposed to and that syringe users probably didn't, resulting in higher insulin costs for the pen users.

Source: EurekAlert; Clinical Therapeutics, August 2007


Categories: Diabetes, Diabetes, Insulin, Novo Nordisk, Pens, Syringes, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 16 comments - Mar 21, 2009

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.